Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0V1SD
|
|||
Former ID |
DCL000728
|
|||
Drug Name |
BP4.879a
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Schizophrenia [ICD-11: 6A20] | Terminated | [1] | |
Company |
Bioprojet
|
|||
Structure |
Download2D MOL |
|||
Formula |
C17H22N4O
|
|||
Canonical SMILES |
CN1C2CCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
|
|||
InChI |
1S/C17H22N4O/c1-20-12-7-8-13(20)10-11(9-12)18-17(22)16-14-5-3-4-6-15(14)21(2)19-16/h3-6,11-13H,7-10H2,1-2H3,(H,18,22)/t11?,12-,13+
|
|||
InChIKey |
DDHAJFBBJWHSBR-YHWZYXNKSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 3 receptor (5HT3R) | Target Info | Antagonist | [2] |
5-HT 3A receptor (HTR3A) | Target Info | Antagonist | [3] | |
Dopamine D3 receptor (D3R) | Target Info | Antagonist | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Dopaminergic synapse | ||||
Serotonergic synapse | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Panther Pathway | 5HT3 type receptor mediated signaling pathway | |||
Reactome | Dopamine receptors | |||
G alpha (i) signalling events | ||||
Ligand-gated ion channel transport | ||||
WikiPathways | Monoamine GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
Nicotine Activity on Dopaminergic Neurons | ||||
GPCRs, Other | ||||
SIDS Susceptibility Pathways | ||||
Iron uptake and transport |
References | Top | |||
---|---|---|---|---|
REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
REF 2 | 5-HT(3A) receptor subunit is required for 5-HT3 antagonist-induced reductions in alcohol drinking. Neuropsychopharmacology. 2004 Oct;29(10):1807-13. | |||
REF 3 | Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J Neurochem. 1993 Feb;60(2):730-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.